3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
22
Neoplasm Metastasis
3
Neoplasms
2
Bulbo-Spinal Atrophy, X-Linked
2
Salivary Gland Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer Metastatic Disease
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Ovarian Neoplasms
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Colorectal Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Bites and Stings
1
Advanced Solid Tumor
1
Adenocarcinoma
1
Interventions
Cisplatin
14
Paclitaxel
12
pembrolizumab
9
Fluorouracil
7
Radiotherapy
6
Irinotecan
5
Esophagectomy
5
tislelizumab
4
Oxaliplatin
4
Leucovorin
4
Drug Therapy
4
Carboplatin
4
toripalimab
3
Levoleucovorin
3
Docetaxel
3
Capecitabine
3
camrelizumab
2
Taxes
2
Radiation
2
Nivolumab
2
Injections
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
sintilimab
1
palbociclib
1
nimotuzumab
1
nazartinib
1
lenvatinib
1
ivarmacitinib
1
futibatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
abiraterone
×
90 days
×
Clear all
No trials found.